Navigation Links
Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
Date:5/24/2012

LEXINGTON, Ky. (May 24, 2012) David Feola, a University of Kentucky College of Pharmacy faculty member in the Department of Pharmacy Practice and Science, received a five-year, $1.8 million grant from the National Institutes of Health (NIH) to continue his research investigating immune responses in the lungs that will potentially lead to the discovery of medical treatments for patients with cystic fibrosis and other chronic pulmonary inflammatory conditions.

Cystic fibrosis is a life-threatening disease that causes mucus in the lungs to become too thick, which leads to severe pulmonary complications. This disease is one of the most common chronic lung diseases in children and young adults, affecting 30,000 children and adults in the United States and nearly 70,000 people worldwide, according to the Cystic Fibrosis Foundation.

Feola's research lab focuses on the regulatory function of macrophages, an immune cell type that kills invading pathogens and controls inflammation, in patients with chronic pulmonary inflammatory diseases. Cystic fibrosis causes progressive, life-threatening lung damage due in large part to repeated, dysregulated inflammatory responses to bacterial infection. Preliminary research in Feola's lab suggests that inducing specific types of macrophage activation could blunt this dysregulated inflammation. This research will lead to discovery of specific drug targets that could slow or halt this destructive cycle of inflammatory injury and pulmonary function decline in these patients.

"It is our hope that this research funding will provide us a greater understanding on how cystic fibrosis works, discover novel ways of treating the disease, and how we might be able to improve quality of life for these patients," said Feola, who also is a two-time graduate of the UK College of Pharmacy. Feola received his PharmD and PhD from the College.

Feola's grant is an investigator-initiated Research Project (R01) award, which is being funded by NIH's National Institute of Allergy and Infectious Diseases. R01 grant funding has become increasingly competitive due to the nation's current economic condition.

"The funding of this NIH grant is a testament to Dr. Feola's skill, expertise, tenacity and perseverance in pursing this support for his research program," said Linda Dwoskin, Associate Dean for Research for the UK College of Pharmacy. "I am extremely happy for him, his lab and the Pharmacy Practice and Science Department. I look forward to hearing about the great discoveries that result from Dr. Feola's research on cystic fibrosis."


'/>"/>

Contact: Allison Elliott
allison.elliott@uky.edu
University of Kentucky
Source:Eurekalert

Related medicine news :

1. McMaster University researchers discover drug destroys human cancer stem cells but not healthy ones
2. University studies and career expectations of medical students
3. University of Minnesota startup to treat challenging bacterial infection
4. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
5. University of Houston Graduate College of Social Work announces partnership with MD Anderson
6. Neuropsychologist receives University of Houstons highest faculty honor
7. Louisiana Tech University professor earns NSF Early Career Development grant
8. Rice University student engineers automate limb lengthening for kids
9. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
10. University of Cincinnati researchers win $3.7M grant from US Department of Defense
11. Oxford University Press partners with the Physical Society of Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... ... ... A Safe Haven Foundation (ASHF) has been selected as one of 26 ... Fund. The fund was created in March to help nonprofits with their immediate response ... vulnerable populations in hard-hit communities. , “We are humbled and honored to be ...
(Date:5/21/2020)... BEDFORD, Mass. (PRWEB) , ... May 21, 2020 ... ... version of its award-winning population health management platform that supports care management and ... more than 100 individuals at client sites, TruCare 2020 provides significant usability and ...
(Date:5/16/2020)... ... May 15, 2020 , ... On May 21, T1V will host a webinar featuring Dr. David ... and a contributor to CBS news, as we address COVID-19 and the impact on unified ... of the country since March, many questions are left unanswered as we look at the ...
(Date:5/15/2020)... ... May 15, 2020 , ... ... solutions, recently announced the company and its healthcare-focused background screening division, PreCheck, were ... Pre-Employment Screening Consulting/Services Companies 2020. A distinguished panel comprising of CEOs, CIOs, CHROs, ...
(Date:5/14/2020)... , ... May 14, 2020 , ... ... addressing unmet needs in the field of urology, today announced that John Pettit, ... UroLift® Center of Excellence. The designation recognizes that Dr. Pettit has achieved a ...
Breaking Medicine News(10 mins):
(Date:5/16/2020)... ... May 16, 2020 , ... Oakworks Medical, a leading manufacturer of Ultrasound, ... help patients lay face down for extended periods and possibly prevent them from needing ... to PTs and Pain Management professionals. We used our expertise to design a proning ...
(Date:5/15/2020)... (PRWEB) , ... May 15, 2020 , ... Prevent ... its new brand identity, logo, and website. The new look will be integrated in ... the sight-saving efforts of Prevent Blindness. , The new identity is designed to ...
(Date:5/14/2020)... AUSTIN, Texas (PRWEB) , ... May 14, 2020 , ... ... Dan Holtzclaw, was selected as one of the World’s Top 100 Doctors in Dentistry ... by a committee of leaders in the dental industry, Dr. Holtzclaw was recognized for ...
Breaking Medicine Technology: